“Impact of Coronavirus/COVID-19 on special/intensive care for newborns – a parents’ perspective”

The worldwide study “Impact of Coronavirus/COVID-19 on special/intensive care for newborns – a parents’ perspective” is unique: It aims at exploring parents’ experiences related to the challenges caused by the current pandemic regarding the care of and access to their newborn baby – voices that are often overheard.

The Coronavirus/COVID-19 pandemic creates exceptional challenges, especially for the care of the most vulnerable groups of patients – such as sick and preterm born children. It is therefore important to explore parents’ experiences related to these challenges as they play a crucial role in the care of their babies – not only at home but also in the hospital setting. Having unique insights into the perceived problems will help identify strengths and weaknesses of the care provision in the context of the crisis response. Finally, conclusions can be drawn for future emergencies and the impact on neonatal care.

We kindly ask parents of sick and preterm babies who were born during this Coronavirus/COVID-19 pandemic to participate in our survey, which is available in 21 languages:

This research is a joint initiative by EFCNI and GLANCE. It is carried out by the Scientific Affairs Department of the European Foundation for the Care of Newborn Infants (EFCNI) ( in collaboration with representatives of parent organisations, COINN (Council of International Neonatal Nurses), ESPR (European Society for Paediatric Research), NIDCAP (Newborn Individualized Developmental Care and Assessment Program), and UENPS (Union of European Neonatal & Perinatal Societies).

We would like to express our greatest appreciation to those who supported us with translating the survey. Numerous members of parent organisations and healthcare professionals have volunteered to make this study available in 21 languages. Thank you!

The Ethics Committee of Maastricht UMC+ officially waived the need for ethics approval.

EFCNI received a donation by Novartis Pharma AG in support of this study.

For further information, please contact: